InsiderTrades

Form 4 for TMCI TREACE MEDICAL CONCEPTS, INC.

Accepted 2025-03-19 00:00:00 ET · period of report 2025-03-17 · accession 0000950170-25-042291 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2025-03-19 2025-03-17 TMCI Scanlan Sean F. Chief Innovation Off S - Sale+OE $7.97 -50.0K 364.1K -12% -$398.5K
DT 2025-03-19 2025-03-17 TMCI Scanlan Sean F. Chief Innovation Off M - OptEx $1.05 +50.0K 414.1K +14% +$52.5K
DT 2025-03-19 2025-03-17 TMCI Scanlan Sean F. Chief Innovation Off M - OptEx $0.00 -50.0K 16.9K -75% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-17 S D 50,000 $7.97 364,081 D — — (F3) The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $7.8800 to $8.0900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) Includes 325,098 restricted stock units.
2 Common Common Stock 2025-03-17 M A 50,000 $1.05 414,081 D — — (F2) Includes 325,098 restricted stock units.
3 Derivative Stock Option (Right to Buy) 2025-03-17 M D 50,000 $0.00 16,875 D $1.05 · 2021-01-30 to 2027-01-30 50,000 Common Stock (F4) The stock option vested in equal annual installments over 4 years, commencing on January 30, 2017 with the last installment vesting on January 30, 2021.